JAMA Network
About The Study: This analysis found that the COVID-19 pandemic was associated with shifts in the focus of payments from pharmaceutical and medical device companies to physicians and teaching hospitals for research and an immediate and sustained decline in payments for marketing. Research payments were stable during the pandemic despite widespread clinical trial suspensions, which may reflect clinical trial adaptations, including virtual study visits and remote outcome measurement.
Authors: Timothy S. Anderson, M.D., M.A.S., of Harvard Medical School in Boston, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamahealthforum.2022.3342)
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
